# Characterization of Multi-dose RVX000222 in Combination With Statin Treatment in Dyslipidemia

> **NCT01863225** · PHASE2 · TERMINATED · sponsor: **Resverlogix Corp** · enrollment: 13 (actual)

## Conditions studied

- Dyslipidemia
- Coronary Artery Disease

## Interventions

- **DRUG:** RVX000222
- **DRUG:** Rosuvastatin
- **DRUG:** Atorvastatin
- **DRUG:** Rosuvastatin
- **DRUG:** Atorvastatin

## Key facts

- **NCT ID:** NCT01863225
- **Lead sponsor:** Resverlogix Corp
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-05
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2015-05-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01863225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01863225, "Characterization of Multi-dose RVX000222 in Combination With Statin Treatment in Dyslipidemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01863225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*